Arctiin alleviates the progression of osteoarthritis by regulating the cholesterol metabolic pathway

Area of Science:

• Biochemistry
• Molecular Biology
• Orthopedics

Background:

• Osteoarthritis (OA) is a degenerative joint disease with complex pathogenesis and limited effective treatments.
• Metabolic syndrome is increasingly linked to OA, highlighting the need for novel therapeutic targets.
• Arctiin (ARC), a natural lignan, possesses anti-inflammatory and anti-osteoporotic properties, suggesting potential OA therapeutic value.

Purpose of the Study:

• To investigate the therapeutic potential of Arctiin (ARC) in osteoarthritis (OA).
• To elucidate the molecular mechanisms underlying ARC's effects on chondrocytes and OA progression.
• To evaluate ARC's impact on cartilage degradation and subchondral bone remodeling in an OA rat model.

Main Methods:

• Cell Counting Kit-8 and toluidine blue staining assessed chondrocyte viability and glycosaminoglycan.
• RT-PCR, Western blotting, and immunofluorescence analyzed gene and protein expression.
• OA rat models underwent histological assessment and micro-CT scanning for in vivo evaluation.

Main Results:

• ARC counteracted IL-1β-induced increases in MMP3, MMP13, and COX-2, and decreases in collagen II and SOX9.
• ARC modulated chondrocyte cholesterol metabolism by inhibiting the CH25H-CYP7B1-RORα axis.
• In vivo, ARC reduced cartilage damage, proteoglycan loss, and subchondral bone osteolysis in OA rats.

Conclusions:

• Arctiin (ARC) effectively inhibits IL-1β-induced inflammatory responses and extracellular matrix degradation in osteoarthritis.
• ARC's therapeutic effects involve the modulation of cholesterol metabolism and suppression of the CH25H/CYP7B1/RORα axis.
• ARC demonstrates significant potential as a therapeutic agent for osteoarthritis, addressing both cartilage and bone pathology.